GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » ROA %

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) ROA % : -86.83% (As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. GreenLight Biosciences Holdings PBC's annualized Net Income for the quarter that ended in Mar. 2023 was $-113.88 Mil. GreenLight Biosciences Holdings PBC's average Total Assets over the quarter that ended in Mar. 2023 was $131.14 Mil. Therefore, GreenLight Biosciences Holdings PBC's annualized ROA % for the quarter that ended in Mar. 2023 was -86.83%.

The historical rank and industry rank for GreenLight Biosciences Holdings PBC's ROA % or its related term are showing as below:

GRNA' s ROA % Range Over the Past 10 Years
Min: -157.86   Med: -110.3   Max: -73.74
Current: -123.88

During the past 4 years, GreenLight Biosciences Holdings PBC's highest ROA % was -73.74%. The lowest was -157.86%. And the median was -110.30%.

GRNA's ROA % is not ranked
in the Biotechnology industry.
Industry Median: -35.515 vs GRNA: -123.88

GreenLight Biosciences Holdings PBC ROA % Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC ROA % Chart

GreenLight Biosciences Holdings PBC Annual Data
Trend Dec19 Dec20 Dec21 Dec22
ROA %
-93.60 -73.74 -126.99 -157.86

GreenLight Biosciences Holdings PBC Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -164.78 -187.76 -121.99 -103.37 -86.83

Competitive Comparison of GreenLight Biosciences Holdings PBC's ROA %

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's ROA % distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's ROA % falls into.



GreenLight Biosciences Holdings PBC ROA % Calculation

GreenLight Biosciences Holdings PBC's annualized ROA % for the fiscal year that ended in Dec. 2022 is calculated as:

ROA %=Net Income (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=-167.055/( (63.058+148.598)/ 2 )
=-167.055/105.828
=-157.86 %

GreenLight Biosciences Holdings PBC's annualized ROA % for the quarter that ended in Mar. 2023 is calculated as:

ROA %=Net Income (Q: Mar. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=-113.876/( (148.598+113.689)/ 2 )
=-113.876/131.1435
=-86.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2023) net income data. ROA % is displayed in the 30-year financial page.


GreenLight Biosciences Holdings PBC  (NAS:GRNA) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2023 )
=Net Income/Total Assets
=-113.876/131.1435
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-113.876 / 15.28)*(15.28 / 131.1435)
=Net Margin %*Asset Turnover
=-745.26 %*0.1165
=-86.83 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


GreenLight Biosciences Holdings PBC ROA % Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines

From GuruFocus